Stock A288330 BRIDGE BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bridge Biotherapeutics, Inc.

Equities

A288330

KR7288330004

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 20/05/2024 am IST 		5-day change 1st Jan Change
2,140 KRW -3.60% Intraday chart for Bridge Biotherapeutics, Inc. -7.16% -34.86%
28/03 Bridge Biotherapeutics Launches Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade CI
26/03 Bridge Biotherapeutics Announces Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 3,17,282 2,79,086 2,79,845 2,30,799 73,111
Enterprise Value (EV) 1 2,48,288 2,21,538 2,36,944 1,82,513 56,475
P/E ratio 139 x -14.4 x -10.6 x -5.52 x -1.6 x
Yield - - - - -
Capitalization / Revenue 5.44 x 44 x 145 x 76.3 x 731 x
EV / Revenue 4.26 x 34.9 x 123 x 60.4 x 565 x
EV / EBITDA 232 x -11.5 x -9.11 x -4.3 x -1.45 x
EV / FCF -9.48 x -31.5 x -25.1 x -8.19 x -3.39 x
FCF Yield -10.5% -3.17% -3.98% -12.2% -29.5%
Price to Book 4.76 x 4.71 x 6.5 x 4.66 x 4.27 x
Nbr of stocks (in thousands) 16,583 19,181 19,707 19,896 22,256
Reference price 2 19,133 14,550 14,200 11,600 3,285
Announcement Date 11/03/20 22/03/21 17/03/22 15/03/23 18/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 58,283 6,340 1,924 3,024 100
EBITDA 1 1,069 -19,220 -26,010 -42,423 -38,925
EBIT 1 617.2 -19,578 -26,392 -43,501 -40,349
Operating Margin 1.06% -308.81% -1,371.6% -1,438.66% -40,349.43%
Earnings before Tax (EBT) 1 7,226 -19,232 -26,278 -41,700 -42,455
Net income 1 1,325 -19,232 -26,278 -41,700 -42,321
Net margin 2.27% -303.35% -1,365.7% -1,379.08% -42,321.05%
EPS 2 137.2 -1,010 -1,345 -2,102 -2,059
Free Cash Flow 1 -26,181 -7,027 -9,435 -22,289 -16,679
FCF margin -44.92% -110.83% -490.37% -737.12% -16,679.09%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 11/03/20 22/03/21 17/03/22 15/03/23 18/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 68,994 57,548 42,901 48,286 16,636
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 -26,181 -7,027 -9,435 -22,289 -16,679
ROE (net income / shareholders' equity) 6.52% -28.7% -51.4% -87.9% -119%
ROA (Net income/ Total Assets) 0.84% -17.1% -29.9% -50.3% -53.6%
Assets 1 1,56,898 1,12,575 87,755 82,908 78,991
Book Value Per Share 2 4,017 3,088 2,184 2,488 769.0
Cash Flow per Share 2 3,432 1,092 416.0 399.0 626.0
Capex 1 494 79.8 165 437 320
Capex / Sales 0.85% 1.26% 8.57% 14.45% 319.51%
Announcement Date 11/03/20 22/03/21 17/03/22 15/03/23 18/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BRIDGE BIOTHERAPEUTICS, INC. Stock Bridge Biotherapeutics, Inc.
-34.86% 4Cr
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.58% 11TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.41% 11TCr
ARGENX SE Stock argenx SE
-2.59% 2.2TCr
BIONTECH SE Stock BioNTech SE
-12.38% 2.19TCr
GENMAB A/S Stock Genmab A/S
-5.29% 1.92TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-3.35% 1.81TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.57% 1.77TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.51% 1.43TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 1.24TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A288330 Stock
  4. Financials Bridge Biotherapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW